Telix and AusHealth Partner for Lung, Ovarian Cancer
Filed with ASX · · 2 pages · English
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Appendix 4C - September 2019 quarter
- Telix to Acquire European Production Facility
- FDA Pre-NDA Meeting Outcomes - TLX591-CDx illumet
- Appendix 4D and Financial Report for half-year to 30 June 19
- First Australian Patient Dosed in ZIRCON Phase III Trial
Later from Telix Pharmaceuticals
- Telix and ATONCO Partner for Bladder Cancer
- Telix and Vic Cancer Centre receive Cancer Australia grant
- Zircon P3 IND submitted to US FDA
- NDA Clinical Briefing Package Submitted to the US FDA
- Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals